Online Sleep Therapy Targets Alcohol Use in Heavy Drinkers with Insomnia
A completed trial tests whether internet-based CBT-I can reduce both insomnia severity and alcohol consumption in heavy-drinking adults.
Summary
This completed clinical trial investigated whether treating insomnia through an internet-based program could also reduce heavy alcohol use. Researchers enrolled 113 community-dwelling adults who were both heavy drinkers and had insomnia. Participants were assigned to either SHUTi — the most validated online cognitive behavioral therapy for insomnia platform — or a web-based insomnia education control program. The core hypothesis is that insomnia and alcohol use disorder are deeply intertwined, and that improving sleep quality may break the cycle driving excessive drinking. This is the first study to test internet-delivered CBT-I specifically in heavy drinkers, making it a potentially scalable, low-barrier intervention. Results could reshape how clinicians approach alcohol use disorder by treating sleep as a primary therapeutic target rather than a secondary concern.
Detailed Summary
Alcohol use disorder (AUD) is one of the most burdensome conditions in modern medicine, carrying enormous physical, psychological, and economic costs. Yet a frequently overlooked driver of AUD is insomnia — a condition that is highly prevalent among heavy drinkers and that actively perpetuates alcohol misuse as individuals self-medicate poor sleep with alcohol. This trial addresses that bidirectional relationship head-on.
Researchers at the University of Kentucky enrolled 113 community-dwelling adults who met criteria for both heavy drinking and insomnia. Participants were randomized to receive either SHUTi (Sleep Healthy Using the Internet), the most widely used and rigorously validated internet-based cognitive behavioral therapy for insomnia (CBT-I) platform, or a web-based insomnia education program serving as an active control. The trial ran from early 2023 through mid-2025.
The primary aims were to reduce both alcohol consumption and insomnia severity. CBT-I is the gold-standard treatment for insomnia and works by restructuring maladaptive sleep behaviors and cognitions without medication. Delivering it online removes traditional access barriers — cost, geography, stigma — making it a potentially scalable public health tool.
This is the first trial to specifically test internet-delivered CBT-I in heavy drinkers, filling a critical gap in the literature. Prior research suggested insomnia treatment could reduce alcohol-related problems, but whether it could prevent the progression to severe AUD in community samples was unknown. If SHUTi reduces both outcomes, it would validate a novel, accessible intervention pathway.
Caveats include the relatively small sample size of 113 participants and the fact that this summary is based solely on the trial registration abstract — no outcome data have been published yet. The non-pharmacological design is a strength for generalizability, but blinding limitations inherent to behavioral trials apply.
Key Findings
- First trial to test internet-based CBT-I specifically in heavy drinkers with comorbid insomnia.
- SHUTi, the most validated online sleep therapy platform, was used as the active intervention.
- Primary endpoints target both insomnia severity and alcohol consumption simultaneously.
- Online delivery removes cost and access barriers, making this a potentially scalable public health tool.
- Trial completed July 2025 with 113 enrolled participants; outcome data not yet published.
Methodology
Randomized controlled trial enrolling 113 community-dwelling adults with both heavy drinking patterns and insomnia. Participants were assigned to either SHUTi (internet-based CBT-I) or a web-based insomnia education control program. The trial was completed in July 2025; this summary is based on the registration record only, as results have not been published.
Study Limitations
This summary is based on the trial registration abstract only; no outcome or efficacy data are available yet. The sample size of 113 is modest, which may limit statistical power for subgroup analyses. Behavioral trials cannot be fully blinded, introducing potential performance and detection bias.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.